PI3K inhibitors in haematological malignancies
Author:
Publisher
Elsevier BV
Subject
Oncology
Reference6 articles.
1. The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint;Richardson;Lancet Oncol,2022
2. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial;Zelenetz;Lancet Oncol,2017
3. Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia;Sharman;J Clin Oncol,2019
4. Idelalisib immune-related toxicity is associated with improved treatment response;Wagner-Johnston;Leuk Lymphoma,2021
5. Medical comorbidities in patients with chronic lymphocytic leukaemia treated with idelalisib: analysis of two large randomised clinical trials;Gordon;Br J Haematol,2021
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study;HemaSphere;2024-08
2. PI3K Inhibitors in Hematology: When One Door Closes…;Clinical Cancer Research;2024-07-05
3. Leniolisib: a novel treatment for activated phosphoinositide-3 kinase delta syndrome;Frontiers in Pharmacology;2024-02-12
4. Interim analysis: Open-label extension study of leniolisib for patients with APDS;Journal of Allergy and Clinical Immunology;2024-01
5. ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms;Molecular Cancer Therapeutics;2023-12-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3